QARRUS™

Local Chemotherapeutic Delivery Platform

Directly target drug to tumor and disrupts major players in cancer progression

The QARRUS™ Microparticle Platform is designed to ensure that chemotherapy reaches a tumor and supporting cells while keeping systemic drug levels well below toxicity limits.

  • Single intratumoral QARRUS injection sustains chemotherapy treatment for weeks or months using safe, established polymers.
  • Unique microparticle design targets tumor associated macrophages (TAMs) and cancer stem cells (CSCs) to impact tumor growth and metastasis.
  • Simulation-driven formulation design supports finely tailored pharmacokinetics for single agents and chemotherapy combinations.

An established tumor presents a robust biology where highly evolvable cancer stem cells synergize with anti-inflammatory macrophage cells to fuel growth and drive metastasis.

Current Challenges

Clinical-stage attrition of new chemotherapeutics

Each year 30-40 chemotherapy drugs fail clinical trials. Almost all of them are administered as simple formulations, such as pills or intravenous solutions. The high annual attrition rates of these chemotherapeutics are often attributable to dose-related toxicity.

Off-target delivery carries hidden risks

Only a fraction of a percent of an intravenous (i.v.) chemotherapy reaches a tumor and impacts its growth.

Off-target delivery:

  • Limits the therapeutic window
  • Reduces the maximum tolerated dose
  • Increases the rate of critical adverse events
  • Increases exposure in healthy tissues

Many of these issues only become apparent in clinical trials after significant investment in R&D and patents.

Systemic formulations offer only marginal improvement

Even simple improvements to a drug’s formulation can dramatically improve its pharmacological profile by targeting its delivery. Both passive and molecularly targeted formulations increase the amount of drug reaching tumors by 1-2 orders of magnitude over simple solutions. Yet these formulations still deliver the majority of their drug to healthy cells resulting in significant toxicity.

QR206’s impact on tumor growth correlates directly with elevated drug levels in tumor and lymph nodes (DLN) relative to equal bolus dose. Data for 26 days post-injection (T-test, *p < 0.15, ** p < 0.09).

QR206’s impact on tumor growth correlates directly with elevated drug levels in tumor and lymph nodes (DLN) relative to equal bolus dose. Data for 26 days post-injection (T-test, *p < 0.15, ** p < 0.09).

Case Study: Qarrus™ in Head and Neck Cancer

qarrus_qr206_diagram

QR206 disperses into regional metastatic sites by targeting phagocytic cells, effectively “chasing down” undetectable, regional metastases

hnc_qarrus_mode_action

Qrono first demonstrated proof-of-concept for QARRUS™ in HNSCC xenografts using epothilone D (EpoD), a tubulin inhibitor that failed clinical trials. A single injection of QARRUS™-formulated EpoD (QR206) significantly outperformed an equivalent bolus of unformulated drug, reducing relative tumor volume 4‑fold over 4 weeks (T-test, *p < 0.04, ** p < 0.02) and maintained systemic exposure 5x below toxicity threshold.

qarrus-vs-unformulated-drug

drug-level-correlation

QR206’s impact on tumor growth correlates directly with elevated drug levels in tumor and lymph nodes (DLN) relative to equal bolus dose.  Data for 26 days post-injection (T-test, *p < 0.15, ** p < 0.09).

Learn more about QARRUS™

Contact Qrono today for an in depth introduction to the QARRUS platform.
We look forward to partnering on improved chemotherapeutics.

Contact Us

Send us an email and we'll get back to you ASAP! Thanks